Expanding Access to Birth Control: OTC Pills, Pharmacists & State Policies

Access to oral contraceptives remains a critical component of reproductive healthcare, and recent developments are reshaping how and where women in the United States can obtain these medications. Although the vast majority of women report using some form of contraception, barriers to consistent access – including cost, logistical challenges, and geographic limitations – persist. New policies and product approvals are aiming to address these hurdles, but awareness and implementation vary significantly.

Contraceptive Access: A Patchwork of Challenges

Data from the 2022 KFF Women’s Health Survey highlights ongoing difficulties. Approximately one-third (33%) of women using hormonal contraception have experienced disruptions in their supply, missing doses due to inability to obtain a timely refill. This issue is particularly acute for the more than 19 million women of reproductive age who live in what are termed “contraceptive deserts” – areas with limited access to publicly funded family planning providers. Power to Decide defines these areas as counties where there are fewer providers per 1,000 women in need of publicly funded contraception.

State and federal policies also play a significant role. Changes in funding and regulations can directly impact the number of family planning providers offering a full range of contraceptive methods. These factors underscore the need for innovative solutions to expand access, and several approaches are gaining traction.

The Rise of Over-the-Counter Options

A major shift occurred in July 2023 with the U.S. Food and Drug Administration (FDA) approval of Opill, a progestin-only daily oral contraceptive pill, for over-the-counter (OTC) use. This marked the first time a daily birth control pill was available without a prescription, offering increased convenience and potentially reducing barriers to access. KFF notes that OTC access is expected to increase contraceptive use and improve continuity of use by saving women time and reducing the need for appointments.

Opill is currently priced at $19.99 for a one-month supply or $49.99 for a three-month supply. Another pharmaceutical company, Cadence, is also pursuing FDA approval for an OTC version of its combined (progestin and estrogen) oral contraceptive pill, Zena. Still, despite the potential benefits, awareness of Opill remains relatively low. Only about a quarter (26%) of women aged 18 to 49 have heard of the new pill, with even lower awareness among uninsured women (17%) and those in rural areas (21%) compared to those with private insurance (29%) and urban/suburban residents (27%).

Insurance Coverage and State-Level Policies

While Opill is available without a prescription, insurance coverage remains a complex issue. The Affordable Care Act (ACA) currently mandates no-cost coverage for contraceptives in most private plans and for Medicaid expansion populations. However, this coverage typically requires a prescription, even for methods available OTC. To fully realize the benefits of OTC access, changes to insurance policies – either through federal or state legislation, or administrative adjustments to the ACA – are needed.

Currently, nine states – California, Colorado, Delaware, Maryland, Maine, New Jersey, New Mexico, New York, and Washington – have laws or regulations requiring state-regulated private health insurance plans to cover OTC contraception without a prescription. New York’s law specifically applies to emergency contraception, while the others cover a broader range of non-prescribed contraceptive drugs. Eight states – California, Illinois, Maryland, Michigan, North Carolina, New Jersey, New York, and Washington – also use state-only funds to cover at least some OTC contraception without a prescription for Medicaid enrollees, though coverage is often limited to emergency contraception or condoms.

Expanding Access Through Pharmacist Prescribing

Another avenue for increasing access is allowing pharmacists to prescribe or dispense oral contraceptives. As of February 2026, 36 states and the District of Columbia have passed legislation permitting pharmacists to do so. However, the specifics of these laws vary considerably. States differ in the type of prescriptive authority granted (collaborative practice agreements, statewide protocols, standing orders), minimum age requirements, the types of contraceptives pharmacists can prescribe, the length of the supply, and whether a prior prescription is needed.

While pharmacist prescribing can remove barriers, challenges remain. Pharmacies may charge consultation fees (potentially as high as $50 in some areas), which insurers are not always obligated to cover. Pharmacies may choose not to participate or may lack pharmacists trained to provide this service. From the pharmacist’s perspective, additional education and training are required, and reimbursement mechanisms are not always in place.

Extended Supplies and Telecontraception

Increasing the dispensing period to 12 months per prescription is another strategy gaining momentum. Currently, many insurers limit supplies to 1-3 packs at a time. Research suggests that receiving a 12-month supply is associated with a 30% reduction in unintended pregnancies compared to receiving a 1-3 month supply. Twenty-nine states and D.C. Now require plans to cover a 12-month supply, though eight of those states do not have laws prohibiting cost-sharing.

Finally, telecontraception – obtaining contraception through online platforms – is becoming increasingly popular. These services allow patients to consult with providers via video or chat, receive prescriptions, and order pills for delivery. Costs vary, with some companies charging consultation fees or membership fees. While many accept insurance, not all do. KFF’s research shows considerable variation in method availability and insurance acceptance among these platforms.

The landscape of oral contraceptive access is evolving rapidly. The FDA approval of Opill, coupled with state-level policies expanding pharmacist prescribing and insurance coverage, represents significant progress. However, continued efforts are needed to address disparities in awareness, affordability, and access, particularly for those in underserved communities.

Looking Ahead: Monitoring Implementation and Addressing Gaps

The coming months will be crucial for monitoring the implementation of these changes and identifying remaining gaps in access. Further research is needed to assess the impact of OTC access on contraceptive use rates and unintended pregnancy rates, particularly among key populations. Policymakers will need to consider strategies to ensure equitable access to all available methods, including addressing insurance coverage issues and supporting the expansion of pharmacist prescribing programs. Ongoing surveillance of contraceptive deserts and targeted interventions will also be essential to ensure that all women have the ability to access the reproductive healthcare they need.